This engineered circRNA mitigates tumor growth by targeting and inhibiting the oncogenic miR-25 in HCC cells, while concurrently blocking the PD-1/PD-L1 signaling within the tumor microenvironment, thereby exerting a synergistic antitumor effect (Figure 7). The gene discussed is CD274; the disease is hepatocellular carcinoma.